Sun Pharma appoints new Whole-time Director, Independent Director

Mumbai: Sun Pharma has recently announced that the Company's Board has approved the appointment of Aalok Shanghvi as a Whole-time Director and Rolf Hoffmann as an Independent Director.

Aalok Shanghvi has been appointed for a term of five years effective from June 1, 2023 and Rolf Hoffmann has been appointed for a term of five years to be effective from the date of allotment of Director Identification Number, the company informed in a BSE filing.

Aalok Shanghvi is the son of Dilip Shanghvi, Managing Director and Promoter of the Company and is the nephew of Sudhir Valia, Non-Executive Director of the Company. 

Rolf Hoffmann has over 29 years of experience managing top 50 worldwide markets with full P&L and cross-functional accountability. Hoffmann has worked with Eli Lilly and Company for over a 17-year period with a balance of in-country management, international regional management and headquarters global executive positions. In his various responsibilities, he established a regulatory and governmental affairs network around the world, developed in-depth commercial capabilities for all geographies including alliances, joint venture, and organic growth strategy. Hoffmann was a highly respected operational leader and presenter with continued upward momentum when recruited by Amgen, where he spent about 12-years at various leadership roles and responsibilities, including P&L accountabilities for all countries around the world including the USA. Hoffmann has served on various board viz., Ferring Holding Inc., New Jersey, USA, Trizell Holding S.A., Lausanne, Switzerland, Shield Therapeutics PLC, Gateshead Quays, UK, EUSA Pharma, Hemel Hempstead, UK, Biotest AG, Dreieich, Germany, Trigemina, Inc., San Francisco, USA and STADA AG, Bad Vilbel, Germany. He currently serves the board of Genmab A/S, Copenhagen, Denmark, Paratek Pharmaceuticals, Inc., Boston, USA, Semdor Pharma Group GmbH, Cologne, Germany and IDT Biologika GmbH, Dessau-Rosslau, Germany.

Hoffmann has received an MBA, Kenan-Flagler Business School, UNC Chapel Hill, North Carolina, 1987, MA - English, The University of Koeln, Koeln, Germany, 1985 and MA - Kinesiology, Deutsche Sporthochschule Koeln, Koeln, Germany, 1985.

Read also: Sun Pharma proposes to fully acquire Taro Pharmaceutical Industries